BR112015016995A2 - uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para a facilitação do surgimento da anestesia geral - Google Patents

uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para a facilitação do surgimento da anestesia geral

Info

Publication number
BR112015016995A2
BR112015016995A2 BR112015016995A BR112015016995A BR112015016995A2 BR 112015016995 A2 BR112015016995 A2 BR 112015016995A2 BR 112015016995 A BR112015016995 A BR 112015016995A BR 112015016995 A BR112015016995 A BR 112015016995A BR 112015016995 A2 BR112015016995 A2 BR 112015016995A2
Authority
BR
Brazil
Prior art keywords
onset
facilitate
receptor agonists
general anesthesia
nicotinic acetylcholine
Prior art date
Application number
BR112015016995A
Other languages
English (en)
Other versions
BR112015016995A8 (pt
BR112015016995B8 (pt
BR112015016995B1 (pt
Inventor
Halldin Christer
Lopez-Lopez Cristina
Feuerbach Dominik
Johns Donald
Sovago Judit
Hall Mcallister Kevin
Weiss Markus
Fendt Markus
Johannes Sjoerd
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015016995A2 publication Critical patent/BR112015016995A2/pt
Publication of BR112015016995A8 publication Critical patent/BR112015016995A8/pt
Publication of BR112015016995B1 publication Critical patent/BR112015016995B1/pt
Publication of BR112015016995B8 publication Critical patent/BR112015016995B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo a invenção consiste no uso de certos agonistas do receptor alfa 7 nicotínico de acetilcolina para a facilitação do surgimento da anestesia geral.
BR112015016995A 2013-01-15 2014-01-13 Uso de agonistas do receptor alfa 7 nicotínico de acetilcolina BR112015016995B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752772P 2013-01-15 2013-01-15
US61/752,772 2013-01-15
PCT/IB2014/058225 WO2014111838A1 (en) 2013-01-15 2014-01-13 Use of alpha 7 nicotinic acetylcholine receptor agonists

Publications (4)

Publication Number Publication Date
BR112015016995A2 true BR112015016995A2 (pt) 2017-07-11
BR112015016995A8 BR112015016995A8 (pt) 2018-01-23
BR112015016995B1 BR112015016995B1 (pt) 2022-02-01
BR112015016995B8 BR112015016995B8 (pt) 2022-07-26

Family

ID=50070639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015016995A BR112015016995B8 (pt) 2013-01-15 2014-01-13 Uso de agonistas do receptor alfa 7 nicotínico de acetilcolina

Country Status (10)

Country Link
EP (1) EP2945633B1 (pt)
JP (1) JP6338223B2 (pt)
KR (1) KR101879920B1 (pt)
CN (1) CN105263495B (pt)
BR (1) BR112015016995B8 (pt)
CA (1) CA2898080C (pt)
ES (1) ES2883232T3 (pt)
MX (1) MX2015009155A (pt)
TW (1) TWI633886B (pt)
WO (1) WO2014111838A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202002990XA (en) 2017-08-04 2020-05-28 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
US20210077478A1 (en) * 2017-11-22 2021-03-18 The Governors Of The University Of Alberta Method of countering respiratory depression via activation of neuronal heteromeric nicotinic acetylcholine receptors
CN114007613A (zh) 2019-02-05 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
EP3920928A4 (en) 2019-02-06 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
RU2391341C2 (ru) 2002-09-25 2010-06-10 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008523058A (ja) 2004-12-10 2008-07-03 アボット・ラボラトリーズ 縮合ビシクロ複素環置換キヌクリジン誘導体
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
ES2525076T3 (es) 2006-05-19 2014-12-17 Abbvie Bahamas Ltd. Derivados de alcanos azabicíclicos sustituidos con bicicloheterociclos condensados activos en el SNC
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN100448468C (zh) * 2006-11-14 2009-01-07 赵玉民 一种口服用于治疗胃病的药粉
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
WO2010043515A1 (en) 2008-10-13 2010-04-22 F. Hoffmann-La Roche Ag Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides
WO2010056622A1 (en) 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JO3250B1 (ar) * 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
PL2637704T3 (pl) * 2010-11-10 2015-08-31 H Lundbeck As Radioznakowane ligandy oparte na fenyloimidazolu
JP2014503568A (ja) * 2011-01-27 2014-02-13 ノバルティス アーゲー ニコチン酸アセチルコリン受容体α７活性化因子の使用
AU2012276651A1 (en) * 2011-06-30 2014-02-06 Toray Industries, Inc. Antipruritic agent

Also Published As

Publication number Publication date
TW201440766A (zh) 2014-11-01
ES2883232T3 (es) 2021-12-07
CN105263495A (zh) 2016-01-20
JP6338223B2 (ja) 2018-06-06
KR20150105469A (ko) 2015-09-16
CA2898080A1 (en) 2014-07-24
JP2016509595A (ja) 2016-03-31
CA2898080C (en) 2018-01-09
WO2014111838A1 (en) 2014-07-24
TWI633886B (zh) 2018-09-01
MX2015009155A (es) 2016-03-04
KR101879920B1 (ko) 2018-07-18
CN105263495B (zh) 2019-05-14
BR112015016995A8 (pt) 2018-01-23
EP2945633A1 (en) 2015-11-25
BR112015016995B8 (pt) 2022-07-26
EP2945633B1 (en) 2021-06-30
BR112015016995B1 (pt) 2022-02-01

Similar Documents

Publication Publication Date Title
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
TWD170335S (zh) 錶
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
BR112016011830A2 (pt) composições bacterianas sinergísticas e métodos para produção e uso das mesmas.
UY4211Q (es) Pizarra para marcadores
UY35500A (es) Indazoles sustituidos con heteroarilo
TWD170776S (zh) 手錶
UY4230Q (es) Bocadillo retorcido para mascota
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
BR112015016995A8 (pt) uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
CL2018002638A1 (es) Ambrisentan para uso en el tratamiento de insuficiencia renal aguda
BR112015016992A8 (pt) uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
ES1078895Y (es) Mantel enrollable.
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
ES1112530Y (es) Mecanismo de frenado en pendiente, para carros, coches o sillas
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol
CR20140489A (es) Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2665 DE 01/02/2022 QUANTO AO INVENTOR.